Does CymaBay Therapeutics Inc. (CBAY) Have the Potential to Rally 45.99% as Wall Street Analysts Expect?Zacks Investment Research • 11/08/23
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/23
CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary CholangitisGlobeNewsWire • 11/01/23
CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023GlobeNewsWire • 10/31/23
CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 10/25/23
CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023GlobeNewsWire • 10/23/23
Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated CirrhosisGlobeNewsWire • 10/23/23
CymaBay's RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023GlobeNewsWire • 10/18/23
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary CholangitisGlobeNewsWire • 09/21/23
CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 09/14/23
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 09/12/23
CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 09/11/23
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day RunningInvestors Business Daily • 09/08/23
CymaBay Therapeutics stock jumps as rare liver disease treatment shows positive resultsMarket Watch • 09/07/23